Xtant Medical Holdings, Inc. XTNT
Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
Management's Discussion and Analysis of Financial Condition and Results of Operations
Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
Last close
0.38
2026-09-04
Market cap
$52.6M
2026-06-30 share count
52-week range
0.27 - 0.95
Valuation FY2025 figures against the last close
P/S0.4x
P/E12.5x
P/FCF5.2x
EV/EBITDA4.0x
Dividend yield—
Diluted EPS0.03
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $133.9M | $117.3M | $91.3M | $58.0M | $55.3M | $53.3M | $64.7M | $72.2M | $82.5M | $90.0M |
| Cost of revenue | $49.7M | $49.1M | $35.8M | $25.8M | $22.8M | $18.9M | $22.2M | $28.7M | $32.5M | $27.7M |
| Gross profit | $84.3M | $68.2M | $55.5M | $32.1M | $32.5M | $34.4M | $42.5M | $43.5M | $50.1M | $62.3M |
| R&D | $2.1M | $2.4M | $1.3M | $915.0K | $870.0K | $657.0K | $932.0K | $1.7M | $2.4M | $3.4M |
| SG&A | $29.4M | $28.7M | $25.9M | $15.5M | $14.4M | $13.5M | $17.3M | $14.3M | $15.2M | $15.8M |
| Total operating expenses | $77.0M | $80.3M | $65.6M | $38.9M | $36.3M | $35.1M | $44.8M | $103.6M | $87.9M | $69.8M |
| Operating income | $7.3M | -$12.1M | -$10.2M | -$6.8M | -$3.9M | -$751.0K | -$2.3M | -$60.1M | -$37.8M | -$7.5M |
| Interest expense | $3.7M | $4.2M | $2.9M | $1.7M | $995.0K | $6.0M | $5.8M | $10.1M | $14.7M | $12.3M |
| Pre-tax income | $7.0M | -$16.3M | -$1.0M | -$8.4M | -$4.8M | -$6.7M | -$8.1M | -$70.1M | -$52.4M | -$19.4M |
| Income tax | $2.0M | $187.0K | $1.7M | $69.0K | — | $296.0K | $98.0K | — | $0 | $50.4K |
| Net income | $5.0K | -$16.4K | $660 | -$8.5M | -$4.8M | -$7.0M | -$8.2M | -$70.1M | -$52.4M | -$19.5M |
| EPS, basic | 0.04 | -0.12 | 0.01 | -0.09 | -0.06 | -0.25 | -0.63 | -5.97 | -34.76 | -18.46 |
| EPS, diluted | 0.03 | -0.12 | 0.01 | -0.09 | -0.06 | -0.25 | -0.63 | -5.97 | -34.76 | -18.46 |
| Shares, diluted (wtd. avg.) | $150.0M | $133.7M | $126.8M | $94.1M | $85.5M | $28.5M | $13.2M | $11.7M | $1.5M | $1.1M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $17.1M | $6.2M | $5.7M | $20.3M | $18.2M | $2.3M | $5.2M | $6.8M | $2.9M | $2.6M |
| Receivables | $17.8M | $20.7M | $21.7M | $10.9M | $7.2M | $6.9M | $10.1M | $10.0M | $12.7M | $19.0M |
| Inventory | $30.3M | $38.6M | $36.9M | $17.3M | $17.9M | $21.4M | $16.1M | $17.3M | $22.4M | $26.3M |
| Total current assets | $78.2M | $67.1M | $64.9M | $49.3M | $44.3M | $31.4M | $32.2M | $34.7M | $39.7M | $49.0M |
| Property, plant and equipment | $6.2M | $10.1M | $8.7M | $5.8M | $5.2M | $4.3M | $4.7M | $7.2M | $9.9M | $15.8M |
| Goodwill | $6.1M | $7.3M | $7.3M | $3.2M | $3.2M | $3.2M | $3.2M | $3.2M | $41.5M | $41.5M |
| Other intangibles | $299.0K | $8.4M | $10.1M | $344.0K | $400.0K | $457.0K | $515.0K | $573.0K | $13.8M | $35.9M |
| Total assets | $94.1M | $93.8M | $92.6M | $60.2M | $54.7M | $41.5M | $43.2M | $46.4M | $105.7M | $144.1M |
| Accounts payable | $3.8M | $7.9M | $7.1M | $3.5M | $2.6M | $2.9M | $2.2M | $6.5M | $9.3M | $10.5M |
| Short-term debt | $3.5M | — | — | $2.3M | — | $16.8M | — | — | — | — |
| Total current liabilities | $29.5M | $28.6M | $23.0M | $15.2M | $11.1M | $25.6M | $9.4M | $12.1M | $25.8M | $31.1M |
| Long-term debt | $11.0M | $22.0M | $17.2M | $9.7M | $11.8M | — | $76.2M | $77.9M | $67.1M | $119.2M |
| Total liabilities | $43.2M | $50.9M | $41.3M | $26.1M | $23.8M | $27.0M | $87.4M | $90.2M | $164.4M | $151.2M |
| Retained earnings | -$254.5M | -$259.5M | -$243.0M | -$243.7M | -$235.2M | -$230.3M | -$223.3M | -$215.0M | -$144.9M | -$92.5M |
| Total equity | $51.0M | $43.0M | $51.3M | $34.2M | $30.9M | $14.5M | -$44.2M | -$43.8M | -$58.7M | -$7.1M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $12.5M | -$11.9M | -$9.5M | -$5.3M | $439.0K | -$731.0K | -$413.0K | $1.2M | -$543.0K | -$14.4M |
| Depreciation and amortisation | $5.2M | $4.2M | $3.2M | $1.3M | $1.3M | $2.1M | $3.1M | $6.6M | $8.4M | $7.2M |
| Stock-based compensation | $2.9M | $4.1M | $2.7M | $2.5M | $2.2M | $1.1M | $515.0K | $694.0K | $212.0K | $523.0K |
| Capital expenditure | $2.4M | $4.1M | $1.5M | $1.8M | $2.1M | $1.5M | $879.0K | $624.0K | $1.6M | $5.8M |
| Investing cash flow | $7.9M | -$3.7M | -$24.8M | -$1.6M | -$1.9M | -$1.3M | -$544.0K | -$367.0K | -$1.6M | -$5.8M |
| Financing cash flow | -$9.6M | $16.1M | $19.7M | $9.0M | $17.5M | -$861.0K | -$603.0K | $3.1M | $2.4M | $16.4M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-029699.
Others in SIC 3841
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| SYK | STRYKER CORP | $116.27B | 36.1x | 11.2% |
| MMM | 3M CO | $86.93B | 28.1x | 1.5% |
| BSX | BOSTON SCIENTIFIC CORP | $69.27B | 24.6x | 19.9% |
| BDX | BECTON DICKINSON & CO | $50.32B | 31.7x | 8.2% |
| DXCM | DEXCOM INC | $33.17B | 42.1x | 15.6% |
| RMD | RESMED INC | $32.94B | 21.9x | 9.9% |
| MDLN | Medline Inc. | $31.35B | — | 11.5% |
| WST | WEST PHARMACEUTICAL SERVICES INC | $23.93B | 50.1x | 6.3% |